IVIEW Therapeutics is at the forefront of ocular therapy, focusing on the development of innovative pharmaceutical solutions aimed at addressing significant unmet medical needs in eye care. The company employs a range of advanced technologies, including TRPM8 Agonist Technology, which targets specific receptors to enhance therapeutic efficacy, and liposomal technology, which improves drug delivery and bioavailability. Additionally, IVIEW utilizes an In-situ Gel Technology (I-Gel) that allows for sustained release of medications, providing prolonged therapeutic effects for conditions such as dry eye, myopia, viral conjunctivitis, and glaucoma.

The company’s commitment to sustainable and innovative drug development is evident in its diverse pipeline, which includes small molecule discovery and gene therapy development. By leveraging these cutting-edge platforms, IVIEW Therapeutics aims to create differentiated products that not only meet the current demands of ocular health but also pave the way for future advancements in ophthalmic treatments. Their focus on innovative drug delivery systems underscores their dedication to enhancing patient outcomes and improving overall vision health.

United States

iVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative therapies for clear vision and healthier eyes.

IVIEW Therapeutics

Company Details